Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207451 · ClinicalTrials.gov registry record · Phase 4
Vorapaxar on Thrombin Generation and Coagulability
A Phase 4 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT03207451 is a Phase 4 study that has completed, run by Inova Health Care Services. The registered enrollment target is 81 participants.
The verdict
NCT03207451, a Phase 4 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
This investigation will be conducted in patients 18-75 years of age with multiple coronary artery disease risk factors (antiplatelet naïve patients) and patients with prior MI or PVD on antiplatelet therapy. Pharmacodynamics will be assessed at multiple time points to assess onset-, maintenance-, and offset-effect of vorapaxar on thrombin generation, platelet reactivity, and plasma/platelet endothelial and inflammatory biomarkers. Safety assessment will be assessed throughout the study.
Interventions
- DRUG Vorapaxar
- DRUG Vorapaxar and Aspirin
- DRUG Vorapaxar and Clopidogrel
- DRUG Vorapaxar, Aspirin, and Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207451
The ClinicalTrials.gov registry entry for NCT03207451 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vorapaxar is the first listed.
NCT03207451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207451 about?
NCT03207451 is a clinical study titled "Vorapaxar on Thrombin Generation and Coagulability". This investigation will be conducted in patients 18-75 years of age with multiple coronary artery disease risk factors (antiplatelet naïve patients) and patients with prior MI or PVD on antiplatelet therapy. Pharmacodynamics will be assessed at multiple time points to assess onset-, maintenance-, an...
What is the current status of trial NCT03207451?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2016-01-01. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT03207451?
The interventions under investigation include: Vorapaxar (DRUG), Vorapaxar and Aspirin (DRUG), Vorapaxar and Clopidogrel (DRUG), Vorapaxar, Aspirin, and Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT03207451?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.